Supplement-Drug treats penicillin-resistant CAP

Levaquin (levofloxacin tablets/injection) recently received a supplemental new drug application from the Food and Drug Adminis tra tion for the treatment of penicillin-resistant S. pneumoniae in community-acquired pneumonia (CAP), says its manufacturer Ortho-McNeil Pharmaceutical in Raritan, NJ. Data provided to the FDA demonstrated that Levaquin was effective in each of 15 cases of pneumonia caused by penicillin-resistant S. pneumoniae, including six cases with bacteremia.